Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 11NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Gynecologic 3Sarcoma 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 2Thoracic 1Plasma cell 1NET 1Head & Neck 1Endocrine 1Classical hematology 1Breast 1

Conditions

Sarcoma, Alveolar Soft Part 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 1atezolizumab 1Taxes 1Specimen Handling 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Has announcements × Sarcoma × Clear all
NCT03141684 2026-05-13

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
63 enrolled 1 FDA
Sarcoma

Sarcoma, Alveolar Soft Part

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡